NAMS

NewAmsterdam Pharma Company N.V.

Healthcare · $2.6B market cap

We can't put a fair value on NAMS right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?

Equity per share growth-30.9% a year✗

Sales growth-36.6% a year✗

Free cash flow growth—?

Return on invested capital-39.3%✗

Follow NAMS

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

2 of the investors we track hold NAMS. In Q2 2026, 1 added. Who we track

Viking Global Investors

Viking Global Investors · as of Q2 2026

$142.5M

4,203,567 shares

Lee Ainslie

Maverick Capital · as of Q2 2026

$110.7M

3,267,802 shares

Moves in Q2 2026

Added: Lee Ainslie

Insider activity

Since Sep 1, 2026: no open-market purchases, 1 sale worth $41K and 2 other filings (stock awards, tax withholding and similar). Why purchases matter

Sales

Smither John W

director · 2026-09-04

Sold

$41K

Other filings

Gunning Robert William

Vice President, Controller · 2026-09-01

Award

$349K

Gunning Robert William

Vice President, Controller · 2026-09-01

Award

3,200 shares

About NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also…

Biotechnology